
Oncology NEWS International
- Oncology NEWS International Vol 12 No 2
- Volume 12
- Issue 2
Ethnic Differences in Breast Cancer Treatments, Outcomes
SEATTLE-A Fred Hutchinson Cancer Research Center study documents important disparities in breast cancer diagnosis, treatment, and survival among American women of various ethnicities. The findings by Christopher Li, MD, PhD, and his colleagues (Arch Intern Med 163:49-56, 2003) are based on data from 11 tumor registries participating in the Surveillance, Epidemiology, and End Results (SEER) program, including 124,934 women diagnosed with first primary invasive breast cancer from 1992 to 1998.
SEATTLEA Fred Hutchinson Cancer Research Center study documents important disparities in breast cancer diagnosis, treatment, and survival among American women of various ethnicities. The findings by Christopher Li, MD, PhD, and his colleagues (Arch Intern Med 163:49-56, 2003) are based on data from 11 tumor registries participating in the Surveillance, Epidemiology, and End Results (SEER) program, including 124,934 women diagnosed with first primary invasive breast cancer from 1992 to 1998.
The analysis showed that blacks, American Indians, Hawaiians, Indians and Pakistanis, Mexicans, South and Central Americans, and Puerto Ricans had a 1.4- to 3.6-fold greater risk of presenting with stage IV breast cancer, relative to non-Hispanic whites. Blacks, Mexicans, and Puerto Ricans were 20% to 50% more likely to receive a first course of surgical and radiation therapy that did not meet the 2000 National Comprehensive Cancer Network (NCCN) guidelines. Blacks, American Indians, Hawaiians, Vietnamese, Mexicans, South and Central Americans, and Puerto Ricans had a 20% to 200% greater mortality risk after a breast cancer diagnosis.
Articles in this issue
over 23 years ago
Some Activity for Gefitinib in Heavily Pretreated Breast Cancerover 23 years ago
Brachytherapy Results Similar for Blacks, Whitesover 23 years ago
Dose-Dense Chemo Ups Survival in Node+ Breast Cancerover 23 years ago
MR Spectroscopy IDs Breast Cancers, Node Involvementover 23 years ago
ODAC Wants More Data on Expanded Casodex Indicationover 23 years ago
SuperGen Submits First NDA Module for Pancreatic Cancer Drugover 23 years ago
Two Added to ONI’s Oncology Nursing Editorial Advisory Boardover 23 years ago
Bortezomib Active in Relapsed/Refractory Myelomaover 23 years ago
Telomerase Potential Cancer BiomarkerNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Related Content


122 Adjuvant Ribociclib (RIB) Plus Nonsteroidal Aromatase Inhibitor (NSAI) in Patients With HR+/HER2− Early Breast Cancer (EBC): NATALEE 5-Year Outcomes



















































